Compare LINK & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINK | LPCN |
|---|---|---|
| Founded | 1984 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.5M | 61.8M |
| IPO Year | 2007 | 2011 |
| Metric | LINK | LPCN |
|---|---|---|
| Price | $3.26 | $7.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $8.67 | ★ $15.00 |
| AVG Volume (30 Days) | 17.1K | ★ 129.0K |
| Earning Date | 05-12-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.18 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,679,000.00 | $1,976,677.00 |
| Revenue This Year | $8.30 | N/A |
| Revenue Next Year | $34.68 | $74.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.76 | $2.52 |
| 52 Week High | $15.15 | $12.37 |
| Indicator | LINK | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 45.90 | 42.23 |
| Support Level | $2.84 | $2.87 |
| Resistance Level | $3.43 | $8.35 |
| Average True Range (ATR) | 0.18 | 0.68 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 30.50 | 20.68 |
Interlink Electronics Inc is a sensor and printed electronics company operating in two principal sensor technology divisions: force/touch sensors, and gas and environmental sensors. It designs, develops, manufactures and sells a range of force-sensing and gas-sensing technologies that incorporate its proprietary materials technology, firmware and software into a portfolio of standard sensor-based products and custom sensor system solutions. Its force-sensing products and solutions include sensor components, subassemblies, modules products that support effective, efficient cursor control and novel three-dimensional user inputs. Its Human Machine Interface technology platforms are deployed in a wide range of markets including consumer electronics, automotive, industrial, and medical.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.